Amendment: SEC Form S-1/A filed by GRI Bio Inc.
$GRI
Biotechnology: Pharmaceutical Preparations
Health Care
As filed with the Securities and Exchange Commission on December 9, 2025.
Registration No. 333-291999
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1 to
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
GRI BIO, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 2834 | 82-4369909 | ||||||
(State or other jurisdiction of incorporation or organization) | (Primary Standard Industrial Classification Code Number) | (I.R.S. Employer Identification Number) | ||||||
2223 Avenida de la Playa, #208
La Jolla, CA 92037
(619) 400-1170
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
W. Marc Hertz, Ph.D.
President and Chief Executive Officer
GRI Bio, Inc.
2223 Avenida de la Playa, #208
La Jolla, CA 92037
(619) 400-1170
(Name, address, including zip code, and telephone number, including area code, of agent for service)
| Copies to: | |||||
Adam Lenain, Esq. Melanie Ruthrauff Levy, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 3580 Carmel Mountain Road, Suite 300 San Diego, California 92130 Tel: (858) 314-1500 | Rick A. Werner, Esq. Alla Digilova, Esq. Haynes and Boone, LLP 30 Rockefeller Plaza, 26th Floor New York, New York 10112 (212) 659-7300 | ||||
Approximate date of commencement of proposed sale to the public:
As soon as practicable after the effective date of this Registration Statement.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||||||||||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||||||||||
| Emerging growth company | ☒ | |||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o
The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY NOTE
GRI Bio, Inc. is filing this Amendment No. 1 to its Registration Statement on Form S-1 (File No. 333-291999) as an exhibits-only filing. Accordingly, this amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has been omitted.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
(1)Exhibits.
| Incorporated by Reference | ||||||||||||||||||||||||||||||||
| Exhibit No. | Description | Filed Herewith | Form | Date | File Number | |||||||||||||||||||||||||||
| 2.1△ | 8-K | 12/13/22 | 001-40034 | |||||||||||||||||||||||||||||
| 2.2 | S-4/A | 02/24/23 | 333-268977 | |||||||||||||||||||||||||||||
3.1 | 10-K | 03/14/25 | 001-40034 | |||||||||||||||||||||||||||||
3.2 | 8-K/A | 05/26/23 | 001-40034 | |||||||||||||||||||||||||||||
4.1 | S-1 | 10/23/20 | 333-249636 | |||||||||||||||||||||||||||||
4.2 | 8-K | 5/13/22 | 001-40034 | |||||||||||||||||||||||||||||
4.3 | 8-K | 07/26/22 | 001-40034 | |||||||||||||||||||||||||||||
4.4 | 8-K | 12/13/22 | 001-40034 | |||||||||||||||||||||||||||||
4.5 | 8-K | 12/13/22 | 001-40034 | |||||||||||||||||||||||||||||
4.6 | S-4 | 12/23/22 | 333-268977 | |||||||||||||||||||||||||||||
4.7 | S-4 | 12/23/22 | 333-268977 | |||||||||||||||||||||||||||||
4.8 | S-4 | 12/23/22 | 333-268977 | |||||||||||||||||||||||||||||
4.9 | S-4 | 12/23/22 | 333-268977 | |||||||||||||||||||||||||||||
4.10 | S-4 | 12/23/22 | 333-268977 | |||||||||||||||||||||||||||||
4.11 | S-4/A | 01/30/23 | 333-268977 | |||||||||||||||||||||||||||||
4.12 | S-1/A | 01/31/24 | 333-276025 | |||||||||||||||||||||||||||||
4.13 | S-1/A | 01/31/24 | 333-276025 | |||||||||||||||||||||||||||||
4.14 | S-1/A | 06/26/24 | 333-280323 | |||||||||||||||||||||||||||||
4.15 | S-1/A | 06/26/24 | 333-280323 | |||||||||||||||||||||||||||||
4.16 | S-1/A | 06/26/24 | 333-280323 | |||||||||||||||||||||||||||||
4.17 | 8-K | 10/22/24 | 001-40034 | |||||||||||||||||||||||||||||
4.18 | 8-K | 10/22/24 | 001-40034 | |||||||||||||||||||||||||||||
4.19 | 8-K | 10/22/24 | 001-40034 | |||||||||||||||||||||||||||||
4.20 | S-1 | 03/24/25 | 333-286072 | |||||||||||||||||||||||||||||
4.21 | S-1 | 03/24/25 | 333-286072 | |||||||||||||||||||||||||||||
4.22 | S-1 | 03/24/25 | 333-286072 | |||||||||||||||||||||||||||||
4.23^ | S-1 | 12/09/25 | 333-291999 | |||||||||||||||||||||||||||||
4.24^ | S-1 | 12/09/25 | 333-291999 | |||||||||||||||||||||||||||||
4.25^ | S-1 | 12/09/25 | 333-291999 | |||||||||||||||||||||||||||||
| Incorporated by Reference | ||||||||||||||||||||||||||||||||
| Exhibit No. | Description | Filed Herewith | Form | Date | File Number | |||||||||||||||||||||||||||
5.1^ | S-1 | 12/09/25 | 333-291999 | |||||||||||||||||||||||||||||
10.1# | 8-K | 08/13/25 | 001-40034 | |||||||||||||||||||||||||||||
10.2# | S-1 | 10/23/20 | 333-249636 | |||||||||||||||||||||||||||||
10.3# | S-1 | 10/23/20 | 333-249636 | |||||||||||||||||||||||||||||
10.4# | S-8 | 08/13/25 | 333-289593 | |||||||||||||||||||||||||||||
10.5# | S-4 | 12/23/22 | 333-268977 | |||||||||||||||||||||||||||||
10.6△ | 8-K | 05/13/22 | 001-40034 | |||||||||||||||||||||||||||||
10.7△ | 8-K | 07/26/22 | 001-40034 | |||||||||||||||||||||||||||||
10.8# | S-4 | 12/23/22 | 333-268977 | |||||||||||||||||||||||||||||
10.9# | S-4 | 12/23/22 | 333-268977 | |||||||||||||||||||||||||||||
10.10△ | 8-K | 12/13/22 | 001-40034 | |||||||||||||||||||||||||||||
10.11△ | 8-K | 12/13/22 | 001-40034 | |||||||||||||||||||||||||||||
10.12 | S-4 | 03/06/23 | 333-268977 | |||||||||||||||||||||||||||||
10.13△ | 10-K | 03/28/24 | 001-40034 | |||||||||||||||||||||||||||||
10.14# | 10-Q | 08/13/25 | 001-40034 | |||||||||||||||||||||||||||||
10.15# | 8-K | 04/21/23 | 001-40034 | |||||||||||||||||||||||||||||
10.16# | S-4/A | 02/24/23 | 333-268977 | |||||||||||||||||||||||||||||
10.17# | S-4/A | 02/24/23 | 333-268977 | |||||||||||||||||||||||||||||
10.18# | S-4/A | 02/24/23 | 333-268977 | |||||||||||||||||||||||||||||
| Incorporated by Reference | ||||||||||||||||||||||||||||||||
| Exhibit No. | Description | Filed Herewith | Form | Date | File Number | |||||||||||||||||||||||||||
10.19# | 8-K | 04/21/23 | 001-40034 | |||||||||||||||||||||||||||||
10.20# | 10-Q | 08/14/23 | 001-40034 | |||||||||||||||||||||||||||||
10.21△ | 8-K | 08/23/23 | 001-40034 | |||||||||||||||||||||||||||||
10.22△ | S-1/A | 01/31/24 | 333-276025 | |||||||||||||||||||||||||||||
10.23 | S-1/A | 01/31/24 | 333-276025 | |||||||||||||||||||||||||||||
10.24△ | S-1/A | 06/26/24 | 333-280323 | |||||||||||||||||||||||||||||
10.25△ | S-1 | 03/24/25 | 333-286072 | |||||||||||||||||||||||||||||
10.26△^ | S-1 | 12/09/25 | 333-291999 | |||||||||||||||||||||||||||||
10.27 | 8-K | 10/22/24 | 001-40034 | |||||||||||||||||||||||||||||
10.28 | 8-K | 05/20/24 | 001-40034 | |||||||||||||||||||||||||||||
| 10.29 | X | |||||||||||||||||||||||||||||||
16.1 | 8-K | 04/15/25 | 001-40034 | |||||||||||||||||||||||||||||
21.1 | S-1/A | 12/04/23 | 333-274972 | |||||||||||||||||||||||||||||
23.1^ | S-1 | 12/09/25 | 333-291999 | |||||||||||||||||||||||||||||
23.2^ | S-1 | 12/09/25 | 333-291999 | |||||||||||||||||||||||||||||
24.1^ | S-1 | 12/09/25 | 333-291999 | |||||||||||||||||||||||||||||
107^ | S-1 | 12/09/25 | 333-291999 | |||||||||||||||||||||||||||||
__________________
Unless otherwise indicated, exhibits are filed herewith.
△ Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission.
# Indicates a management contract or any compensatory plan, contract or arrangement.
^ Previously filed.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in La Jolla, California, on this 9th day of December, 2025.
| GRI BIO, INC. | |||||
| By: | /s/ W. Marc Hertz, Ph.D. | ||||
| W. Marc Hertz, Ph.D. | |||||
| President and Chief Executive Officer | |||||
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date | ||||||||||||
/s/ W. Marc Hertz, Ph.D. | President, Chief Executive Officer and Director | December 9, 2025 | ||||||||||||
W. Marc Hertz, Ph.D. | (Principal Executive Officer) | |||||||||||||
| * | Chief Financial Officer | December 9, 2025 | ||||||||||||
| Leanne Kelly | (Principal Financial and Accounting Officer) | |||||||||||||
| * | Director and Chairperson of the Board | December 9, 2025 | ||||||||||||
| David Szekeres | ||||||||||||||
| * | Director | December 9, 2025 | ||||||||||||
| David Baker | ||||||||||||||
| * | Director | December 9, 2025 | ||||||||||||
| Roelof Rongen | ||||||||||||||
| * | Director | December 9, 2025 | ||||||||||||
| Camilla V. Simpson, M.Sc. | ||||||||||||||
| *By: | /s/ W. Marc Hertz, Ph.D. | ||||
| W. Marc Hertz, Ph.D. | |||||
| Attorney-in-fact | |||||